Moleculin Biotech (MBRX) announced the release of its Soft Tissue Sarcoma Lung Mets KOL Webcast discussing the final data from its U.S. Phase 1B/2 clinical trial evaluating Annamycin as monotherapy for the treatment of soft tissue sarcoma lung metastases. For the event, Walter Klemp, Chairman and Chief Executive Officer, and Dr. Paul Waymack, Senior Chief Medical Officer of Moleculin are joined by Key Opinion Leaders: Mohamad Cherry, MD, Medical Director of Hematology at Atlantic Health System; Prof. Bernd Kasper, Sarcoma Unit of the Mannheim Cancer Center at the Mannheim University Medical Center, University of Heidelberg; and Sant P. Chawla, MD, Director, Sarcoma Oncology Center, Director, Cancer Center of Southern California.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on MBRX:
- Moleculin Biotech Stock (MBRX) Dives 10% on Clinical Trial Results
- Morning News Wrap-Up: Wednesday’s Biggest Stock Market Stories
- Moleculin Biotech Reports Positive Annamycin Trial Results
- Moleculin Biotech reports efficacy results from Phase 1B/2 trial of annamycin
- Moleculin Biotech files to sell 10.99M shares of common stock, warrants